| 查看: 237 | 回复: 0 | ||
[求助]
Xadago - EPAR - Public assessment report + 临床药学 + 2015/04/09
|
求专业人士帮忙翻译Safinamide的药学临床研究资料，先在此谢过了！！！ 2.8.2.3. Impulsive-compulsive disorders Safinamide also was not associated with an increase in impulsive/compulsive behavior, as assessed by the QUIP (Parkinson's Disease Impulsive-Compulsive Disorders Questionnaire, a self-administered questionnaire specifically designed to assess the severity of symptoms of impulse control disorders (e.g.pathological gambling, buying, eating, and sexual behaviour) in patients with Parkinson’s disease. The QUIP was performed in two studies: Study 27918 (MOTION) and 27919 (SETTLE). Data analysed from overall Group 1 safety population of MOTION and SETTLE showed that changes from baseline in the QUIP scale were similar in the safinamide and placebo groups. Among all subjects who received safinamide, 272 subjects (74.5%) showed no compulsive behaviour at baseline, as evaluated by the QUIP Scale; 49 subjects (13.4%) displayed one act of a compulsive behaviour and 44 subjects (12.1%) displayed 2 or more acts of compulsive behaviour at baseline. Post-baseline evaluations indicated no significant changes, showing that 55 subjects (15.1%) had one act of a compulsive behaviour and 46 (12.6%) displayed 2 or more acts of compulsive behaviour as worst post-baseline values. The incidence is similar to placebo patients. Similar shifts from baseline to worst post-baseline evaluations were observed in safinamide treatment groups, to those seen in the placebo group. |
回复此楼» 猜你喜欢
职称评审没过，求安慰
已经有49人回复
-
26申博自荐
已经有3人回复
-
A期刊撤稿
已经有4人回复
-
垃圾破二本职称评审标准
已经有17人回复
-
投稿Elsevier的Neoplasia杂志，到最后选publishing options时页面空白，不能完成投稿
已经有22人回复
-
EST投稿状态问题
已经有7人回复
-
毕业后当辅导员了，天天各种学生超烦
已经有4人回复
-
三无产品还有机会吗
已经有6人回复